TipRanks
Advertisement

VIOO - ETF AI Analysis

Compare

Top Page

VIOO

Vanguard S&P Small-Cap 600 ETF (VIOO)

Rating:66Neutral
Price Target:
VIOO, the Vanguard S&P Small-Cap 600 ETF, has a solid overall rating driven by several strong small-cap holdings that combine healthy financial performance with generally positive outlooks. Standout contributors like Corcept Therapeutics and Jackson Financial support the fund’s quality through strong earnings, reasonable valuations, and favorable technical trends, while names such as ViaSat and Glaukos add growth but also introduce risks around leverage, profitability, and overvaluation. The main risk factor is the ETF’s focus on small-cap companies, which can mean higher volatility and sensitivity to financial and operational challenges compared with larger, more established firms.
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and over the past few months, showing solid recent momentum in its small-cap holdings.
Broad Sector Diversification
Holdings are spread across many sectors, including financials, industrials, technology, health care, and others, which helps reduce the impact if any one industry struggles.
Low Expense Ratio
The fund’s very low ongoing fee means more of the ETF’s returns stay in investors’ pockets instead of going to costs.
Negative Factors
Heavy U.S. Focus
With almost all assets in U.S. companies, the ETF offers little geographic diversification and is highly tied to the U.S. economy.
Small-Cap Volatility Risk
Because it focuses on smaller companies, the fund can be more sensitive to market swings and economic slowdowns than large-cap funds.
Top Holdings Concentrated in a Few Names
Although each position is relatively small, the fund’s performance can still be influenced by a handful of top holdings, some of which have shown very strong but potentially more volatile price moves.

VIOO vs. SPDR S&P 500 ETF (SPY)

VIOO Summary

Vanguard S&P Small-Cap 600 ETF (VIOO) is a fund that follows the S&P SmallCap 600 Index, giving you a basket of 600 smaller U.S. companies across many industries, including financials, technology, health care, and more. It holds names like Match Group and Molina Healthcare, so you’re getting exposure to businesses that may still be in earlier growth stages. Someone might invest in VIOO to add diversification and growth potential beyond large, well-known companies. A key risk is that small-cap stocks can be more volatile, so the ETF’s value can rise and fall more sharply than the overall market.
How much will it cost me?The Vanguard S&P Small-Cap 600 ETF (VIOO) has an expense ratio of 0.10%, which means you’ll pay $1 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks the S&P SmallCap 600 Index, keeping costs low.
What would affect this ETF?The Vanguard S&P Small-Cap 600 ETF (VIOO) could benefit from economic growth and innovation, as small-cap companies often thrive in expanding markets and are key drivers of new technologies. However, it may face challenges during periods of economic uncertainty or rising interest rates, which can disproportionately impact smaller firms. Its exposure to sectors like financials, technology, and consumer cyclical industries makes it sensitive to regulatory changes and shifts in consumer spending patterns.

VIOO Top 10 Holdings

VIOO’s story is all about U.S. small caps, with health care and consumer names doing much of the heavy lifting. Biotech players like Corcept Therapeutics and Protagonist Therapeutics have been rising steadily, giving the fund a shot of growth, while Glaukos adds more momentum from the medical side. On the consumer front, Brinker International has been heating up as restaurant demand improves, and Match Group is contributing with more mixed but generally positive moves. Offsetting some of this strength, ViaSat and Element Solutions have been lagging, reminding investors that small caps can be a bumpy ride.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Corcept Therapeutics0.60%$39.17M$12.19B54.78%
76
Outperform
ViaSat0.58%$37.42M$10.24B143.24%
56
Neutral
Glaukos0.54%$35.06M$9.87B102.09%
61
Neutral
Match Group0.51%$32.91M$9.73B12.29%
66
Neutral
Brinker International0.51%$32.82M$8.87B38.28%
70
Neutral
Jackson Financial Incorporation0.47%$30.53M$9.35B41.26%
73
Outperform
Ryman0.47%$30.19M$8.32B21.78%
66
Neutral
Element Solutions0.46%$30.11M$8.37B30.47%
65
Neutral
Formfactor0.46%$29.64M$8.98B281.39%
68
Neutral
Protagonist Therapeutics0.46%$29.57M$9.59B151.75%
68
Neutral

VIOO Technical Analysis

Technical Analysis Sentiment
Negative
Last Price
Price Trends
50DMA
135.17
Negative
100DMA
132.36
Negative
200DMA
124.67
Positive
Market Momentum
MACD
-1.56
Positive
RSI
32.32
Neutral
STOCH
14.24
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VIOO, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 133.52, equal to the 50-day MA of 135.17, and equal to the 200-day MA of 124.67, indicating a neutral trend. The MACD of -1.56 indicates Positive momentum. The RSI at 32.32 is Neutral, neither overbought nor oversold. The STOCH value of 14.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VIOO.

VIOO Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$4.13B0.07%
66
Neutral
$107.03B0.06%
65
Neutral
$16.23B0.03%
66
Neutral
$8.90B0.25%
67
Neutral
$6.40B0.28%
63
Neutral
$4.13B0.15%
66
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VIOO
Vanguard S&P Small-Cap 600 ETF
129.84
19.05
17.19%
IJR
iShares Core S&P Small Cap ETF
SPSM
SPDR Portfolio S&P 600 Small Cap ETF
FNDA
Schwab Fundamental US Small Co. Index ETF
FESM
Fidelity Enhanced Small Cap ETF
SMLF
iShares MSCI USA Small-Cap Multifactor ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement